Boston-based biotechnology company Elektrofi revealed on Wednesday that it has appointed Paul Herbert to the role of senior vice president of Pharmaceutical Development.
The company said Herbert is a highly experienced senior executive with a proven track record of about 30 years in the pharmaceutical industry.
Herbert is a an expert in product development and manufacturing for particle-based products and has led the development of twelve processes to NDA submission.
Before joining Elektrofi, Herbert served as vice president of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing.
Elektrofi is focused on improving administration for a range of medicines, such as monoclonal antibodies, therapeutic proteins and other large molecule drugs. The company's breakthrough formulation platform is designed to enable stabilized, highly concentrated formulations for subcutaneous administration.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business